Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market is expected to reach US$ 62,001.00 thousand by 2028


PRESS RELEASE BY The Insight Partners 30 Sep 2021

Share this press on


Hydrogen-predominant SIBO Segment to Dominate Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market during 2021–2028    

According to The Insight Partners market research study on “Europe Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Diagnosis and Type” is expected to reach US$ 62,001.00 thousand by 2028 from US$ 46,628.70 thousand in 2021. The market is estimated to grow at a CAGR of 4.2% from 2021 to 2028. The report provides trends prevailing in the Europe small intestinal bacterial overgrowth (SIBO) diagnostics market along with the drivers and restraints pertaining to the market growth.Advantages of breath test and increasing prevalence of IBS and SIBO are the major factor driving the growth of the Europe small intestinal bacterial overgrowth (SIBO) diagnostics market. However, problems of diagnosis such as agreement issues hinders the growth of Europe small intestinal bacterial overgrowth (SIBO) diagnostics market.       

In case of COVID-19, Europe is highly affected specially France followed by Italy and Spain. These countries also registered maximum deaths in the past few months. Several countries in the Europe imposed social distancing and lockdown policies to prevent the spread of virus. Moreover, disturbances in production as well as transportation had negative impact on the growth of Europe small intestinal bacterial overgrowth diagnostics market. Due to the lockdown and medical emergency various trades were put on hold. Therefore, the receiving the product on time have delayed various laboratory workflow and have resulted in a long process of deliveries of laboratory equipment, medical devices, and consumables. In addition, rapid and sudden emergence of coronavirus disease in Europe postponed all elective diagnostic and surgical procedures. For instance, according to a recent study published by the American Journal of Managed Care in 2021, the healthcare facilities in UK witnessed around 80.0% reduction in number of diagnostic procedures due to lockdown and social distancing policies. This factor is significantly responsible for negative impact on the growth of Europe SIBO diagnostics market. Thus, the delayed processes in the healthcare sector is expected to show slow growth for Europe's small intestinal bacterial overgrowth (SIBO) diagnostics market in the coming few years.

The Europe small intestinal bacterial overgrowth (SIBO) diagnostics market has been segmented based on diagnosis, type, and country. Based on diagnosis, the market has been segmented into breath testing, small intestine aspirate and fluid culture test, blood test, and others. The breath testing segment dominated the market in 2020 and also expected to be fastest growing during forecast period. The breath testing has been further segmented into 14c xylose breath test, hydrogen breath test, 14c glycocholic acid breath test, and malabsorption tests. Based on type, the market has been segmented into hydrogen-predominant SIBO, methane-predominant SIBO, and recurrent SIBO. The hydrogen-predominant SIBO segment dominated the market in 2020 and also expected to be fastest growing during forecast period. Based on country, the market has been segmented into the UK, Germany, France, Italy, Spain, and rest of Europe.

Aerodiagnostics, LLC.; Commonwealth Diagnostics International; Genova Diagnostics; SIBOTest; and The Functional Gut Group are among the leading companies in the Europe small intestinal bacterial overgrowth (SIBO) diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, Commonwealth Diagnostics International (CDI), Inc., announced the commercial re-launch of IBSchek, the first clinically validated biomarker blood test for diarrhea-predominant and mixed-type Irritable Bowel Syndrome (IBS-D, IBS-M) in a new at-home capillary collection kit.       

Contact Us
 
Phone: +1-646-491-9876
Download Free PDF Brochure